Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
James Udelson MD
James E. Udelson MD Advisory Board
Douglas Zipes MD
Douglas P. Zipes MD Editor-in-Chief
Deepak Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI
Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI Advisory Board
See All Experts
story of the week
Published in Cardiology and
1 other channel

Journal Scan / Research · September 13, 2017

Effect of Interleukin-1β Inhibition With Canakinumab on Incident Lung Cancer in Patients With Atherosclerosis

The Lancet

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Peter Libby MD

The Lancet
Effect of Interleukin-1β Inhibition With Canakinumab on Incident Lung Cancer in Patients With Atherosclerosis: Exploratory Results From a Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 2017 Aug 25;[EPub Ahead of Print], PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated